title: [A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
abstract: A 42-year-old woman with multiple organ metastases from breast cancer was successfully treated with 5'-deoxy-5-fluorouridine (5'-DFUR) and hormonal therapy (leuprorelin+tamoxifen). She underwent radical mastectomy for advanced left breast cancer in June 1998. In September 2000, she was treated with docetaxel for multiple lung metastases, and the lesions were diagnosed as in complete remission. In June 2001, she received radiation for bone metastasis in left femoral and received a resection of subcutaneous metastases in the face. Then she received 2 courses of paclitaxel. In May 2002, she had multiple lung metastases, right adrenal metastasis, tumor thrombus in the inferior vena cava and multiple bone metastases, and was treated with cycrophosphamide, epirubicin, and 5-FU, however, they were abandoned due to severe leucopenia. Therefore, 600 mg/day of 5'-DFUR was administered from December 2002. The lesions of lung and adrenal decreased extendedly in March 2003. She was diagnosed as being in CR in March 2004, and this condition has continued to the present.
authors.affiliation: Dept of Surgery, Nagoya Daini Red Cross Hospital.
authors.forename: Eiji
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Komatsu
authors.forename: Takashi
authors.initials: T
authors.lastname: Hiromatsu
authors.forename: Keita
authors.initials: K
authors.lastname: Itazu
authors.forename: Tomotake
authors.initials: T
authors.lastname: Tabata
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kawai
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Fukami
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D015409:Mastectomy, Radical; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D013629:Tamoxifen / Q000008:administration & dosage; D014682:Vena Cava, Inferior / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005467:Floxuridine; D013629:Tamoxifen; D015251:Epirubicin; D003520:Cyclophosphamide; D016729:Leuprolide; C025034:doxifluridine